Genetically predicted lower levels of sclerostin were associated with lower levels of HDL cholesterol, with beta = −0.15 [−0.2, −0.09], higher odds of coronary artery disease, with OR = 1.25 [1.01, 1.55] and higher odds of type 2 diabetes, with OR = 1.45 [1.11, 1.90]. Here, SOST is linked to coronary artery disorder.